Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus
Teresa Broquetas,José A Carrión
DOI: https://doi.org/10.2147/HMER.S291976
2022-07-29
Hepatic Medicine: Evidence and Research
Abstract:Teresa Broquetas, 1, 2 José A Carrión 1– 3 1 Liver Section, Gastroenterology Department, Hospital del Mar, Barcelona, Spain; 2 IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; 3 Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain Correspondence: José A Carrión, Liver Section, Gastroenterology Department, Hospital del Mar, 25-29 Passeig Marítim, Barcelona, 08003, Spain, Tel +34 93 2483220, Fax +34 93 2218644, Email The hepatitis B virus (HBV) infection remains a global public health problem. This review presents updated recommendations for the optimal current treatment of choice with nucleos(t)ide analogues (NA). Current clinical practice guidelines on the management of chronic hepatitis B (CHB) by the Asian Pacific Association for the Study of the Liver, the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases have been considered. Patients with chronic HBV infection are at increased risk of liver disease progression to cirrhosis and hepatocellular carcinoma (HCC) development. The main goal of therapy is to improve survival preventing disease progression and HCC. The induction of long-term suppression of HBV replication represents the main endpoint of current treatment strategies, while hepatitis B surface antigen (HBsAg) loss is the optimal endpoint. The typical indication for treatment requires elevated HBV desoxyribonucleic acid (DNA), elevated alanine aminotransferase and/or at least moderate histological lesions, while all cirrhotic patients with detectable HBV DNA should be treated. The long-term administration of a potent NA with high barrier to resistance, ie, entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide, represents the treatment of choice. However, HBsAg seroclearance is anecdotal with NA. Treated patients should be monitored for therapy response, adherence, risk of disease progression, and risk of HCC development. This review aims to assess the evolving trends on the potent NA and the new perspectives on finite therapy. Keywords: antiviral therapy, efficacy, HBsAg loss, kinetics, treatment cessation The hepatitis B virus (HBV) infection remains a global public health problem. Chronic HBV infection is defined as serum detection of hepatitis B surface antigen (HBsAg) for at least 6 months after infection. The World Health Organization (WHO) estimates that there are 257 million people infected with HBV in the world (around 3.5% of the world's population) causing in 2015 more than 887,000 deaths by cirrhosis and hepatocellular carcinoma (HCC). 1 The prevalence of HBV infection varies in different geographical areas. It is higher in the Western Pacific region and in Africa (around 6%) and lower in the Eastern Mediterranean (3.3%), Southeast Asia (2.0%) and Europe (1.6%). 1 The prevalence is decreasing in several countries due to improvements in the socioeconomic status, universal vaccination programs, and effective antiviral treatments. 2 However, population movements and migration are changing the prevalence and incidence in other countries. Currently, the long-term administration of a nucleos(t)ide analogue (NA) with high barrier to resistance, ie, entecavir (ETV), tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) represents the treatment of choice for chronic hepatitis B (CHB) because these drugs can suppress HBV desoxyribonucleic acid (DNA). However, long-term therapy is needed to maintain the HBV suppression and several issues such as increased cost, reduced adherence, and loss to follow-up should be taken into account. New strategies for limiting the treatment duration should be evaluated. This review aims to assess the evolving trends in first-line NA and the new perspectives on finite therapy. The HBV is a DNA virus that belongs to the Hepadnaviridae family. 3 The virus replicates and assembles in the host's hepatocytes, and the virions are released through the cell secretory pathways. After the virus enters the hepatocytes, the HBV is transported to the nucleus to release the relaxed circular DNA (rcDNA) genome. In the nucleoplasm, the rcDNA becomes a covalently closed circular DNA (cccDNA) that can use the host-cell DNA repair mechanism and can serve as a transcription template for all viral transcripts that are translated into the different viral proteins. 4 In addition to complete infectious virions, infected cells produce free, non-infectious sub-viral spherical or filamentous particles. 5 Integration of the viral genome into the host genome may occur randomly; it is not necessary for viral replication, but it is one of the mechanisms involved in the hepatocyte transformation and carcinogenesis. 6 P -Abstract Truncated-